News Sentiment

LTRN sentiment intelligence

Lantern Pharma Inc news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed
Weighted score 58 Balanced news tone 57 relevant articles
Exchange NASDAQ United States
Sector Healthcare Market context
Industry Biotechnology Read-through group
Latest close 3.60 Week of 10 Jul 2026
Weighted tone 58/100

Balanced news tone

Market reaction Price moving ahead of tone

Price is moving more forcefully than the current news tone suggests.

Primary event Market update

79/100 classification confidence.

Company focus 49

directly relevant articles

Source quality 0

high-authority source matches

Trend context Trend active

-9.3% over one week, -7.2% over four weeks, trend active, and near fair-value range.

Latest direct headline Positive

New to The Street Show #761 to Broadcast Across Bloomberg U.S., Latin America and MENA, Featuring Sagtec Global, Virtuix, Lantern Pharma and YY Group

Market Reaction

Price moving ahead of tone

67/100 confidence

Price is moving more forcefully than the current news tone suggests.

Primary event Market update 79/100 classification
One-week reaction -9.3% Price reacting lower
Trend fit Trend active -7.2% over four weeks
Fair value -10.1% Near fair-value range

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 19
Neutral 35
Negative 3

Relevance

Why the article matched

Direct first
Direct company coverage 49
Industry context 8
Sector context 0

Sources

Coverage mix

Publishers
Stock Titan 9
Market source 8
TradingKey 5
Business Wire 4
TradingView 3
BioSpace 3
Investing.com 3
GuruFocus 3

Event Lens

What the news is about

Classified themes
Market update 30
Earnings 19
Balance sheet 3
Analyst action 2
Capital return 2
Regulatory and legal 1

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 1-30 of 57
Newswire.com Direct company coverage

New to The Street Show #761 to Broadcast Across Bloomberg U.S., Latin America and MENA, Featuring Sagtec Global, Virtuix, Lantern Pharma and YY Group

New to The Street will broadcast Show #761 as sponsored programming across Bloomberg Television in the U.S., Latin America, and MENA. The program features executive interviews with Sagtec Global, Virtuix Holdings, Lantern Pharma, and YY Group Holding, discussing their growth stra

Tone
Positive 71/100
Event
Market update
Published
11 Jul 2026 19:41
Source
Newswire.com
Business Wire Direct company coverage

Lantern Pharma Launches ZetaOmics™ — an Autonomous, Intelligent “Computational Biologist” That Brings Expert-Grade Bioinformatics, Biostatistics & Reasoning to Every Cancer

Lantern Pharma has launched ZetaOmics, an AI-driven "Computational Biologist" module as part of its withZeta.ai platform, designed to bring expert-grade bioinformatics and biostatistics to all cancer types, particularly rare and pediatric cancers. ZetaOmics autonomously designs e

Tone
Positive 92/100
Event
Market update
Published
08 Jul 2026 11:40
Source
Business Wire
Simply Wall Street Direct company coverage

Lantern Pharma (Nasdaq:LTRN) - Analyse des actions

This Simply Wall St report analyzes Lantern Pharma (LTRN), highlighting its focus on oncology drug discovery and development using AI. The company has a low financial score due to forecasted declining earnings, minimal revenue, and current unprofitability, yet it boasts a strong

Tone
Positive 61/100
Event
Earnings
Published
07 Jul 2026 06:09
Source
Simply Wall Street
TradingView Direct company coverage

Lantern Pharma, Inc. Actuals & Estimates (BOATS:LTRN)

This article provides an overview of Lantern Pharma Inc. (LTRN) on the BOATS exchange, detailing its financials, analyst estimates, and historical stock performance. It includes information on earnings, revenue, net income, employee count, and answers frequently asked questions a

Tone
Positive 66/100
Event
Earnings
Published
26 Jun 2026 12:39
Source
TradingView
TradingView Direct company coverage

LTRN Forecast — Price Target — Prediction for 2027

This article provides a detailed forecast and price target for Lantern Pharma Inc. (LTRN) stock, including analyst opinions, historical performance data, and key financial metrics. It covers the current stock price, volatility, market capitalization, upcoming earnings reports, an

Tone
Positive 66/100
Event
Analyst action
Published
26 Jun 2026 06:38
Source
TradingView
Stock Titan Direct company coverage

[EFFECT] Lantern Pharma Inc. SEC Filing

This article announces an SEC filing by Lantern Pharma Inc. (LTRN) for Form EFFECT, indicating a neutral impact and sentiment. The filing pertains to a Notice of Effectiveness for Form S-1, with an effective date of June 18, 2026. The article also provides key company details, re

Tone
Neutral 50/100
Event
Market update
Published
22 Jun 2026 10:10
Source
Stock Titan
TradingKey Direct company coverage

Lantern Pharma Inc (LTRN) Valuation: PE, PB & Fair Value Analysis

The article provides a valuation analysis for Lantern Pharma Inc (LTRN), showing its current stock price and market capitalization. It highlights that key valuation data such as P/E, P/B, P/S, and P/CF ratios have not yet been disclosed by the company. The content primarily serve

Tone
Neutral 50/100
Event
Market update
Published
18 Jun 2026 03:41
Source
TradingKey
TradingKey Direct company coverage

Lantern Pharma Inc (LTRN) Technical Analysis: Support, Resistance, Indicators & Moving Averages

This article provides a technical analysis of Lantern Pharma Inc (LTRN), including its current stock price, market cap, and a breakdown of various technical indicators and moving averages. It highlights that while support and resistance data are not disclosed, the indicators show

Tone
Positive 66/100
Event
Market update
Published
18 Jun 2026 01:41
Source
TradingKey
TradingKey Direct company coverage

Lantern Pharma Inc (LTRN) Earnings Forecast: Future EPS & Revenue Growth Estimates

This article provides an earnings forecast for Lantern Pharma Inc (LTRN), including future EPS and revenue growth estimates. Based on one analyst, the stock has a "Buy" rating with a target price indicating significant upside. The report also covers recent EPS performance and upc

Tone
Positive 71/100
Event
Earnings
Published
18 Jun 2026 01:41
Source
TradingKey
TradingKey Direct company coverage

Lantern Pharma Inc (LTRN) Dividends & Stock Splits: Historical Payouts and Event Timeline

This article provides an overview of Lantern Pharma Inc's (LTRN) dividend and stock split history. It notes that the company has not distributed any dividends over the past five years and has no recorded stock split data. The piece includes current stock information such as price

Tone
Neutral 50/100
Event
Capital return
Published
17 Jun 2026 17:40
Source
TradingKey
Stock Titan Direct company coverage

Lantern Pharma (NASDAQ: LTRN) files S-1 resale and flags funding risk

Lantern Pharma (NASDAQ: LTRN) has filed an S-1 registration statement for the resale of 2.24 million shares of common stock tied to warrants from a May 2026 financing. The company will not receive proceeds from these resales, but may acquire up to $5.1 million if all warrants are

Tone
Negative 14/100
Event
Market update
Published
12 Jun 2026 20:40
Source
Stock Titan
Stocktwits Direct company coverage

Why Did LTRN Stock Surge 18% In Pre-Market Today?

Lantern Pharma Inc. (LTRN) saw its stock surge by 18% in pre-market trading after the FDA cleared its Investigational New Drug application for STAR-001, allowing the company to begin a Phase 1 pediatric clinical trial for central nervous system cancers. STAR-001 was discovered us

Tone
Positive 75/100
Event
Regulatory and legal
Published
12 Jun 2026 06:40
Source
Stocktwits
BioSpace Direct company coverage

Lantern Pharma Reports HARMONIC™ Data Showing LP-300 Progression-Free Survival Benefit Deepens with Treatment Duration in EGFR Exon 21 L858R Lung Cancer

Lantern Pharma reported clinical data from its Phase 2 HARMONIC™ trial for LP-300 in EGFR Exon 21 L858R-mutant NSCLC, showing that progression-free survival benefit for LP-300 deepens with treatment duration, especially in the L858R subgroup. Patients treated through six cycles a

Tone
Positive 73/100
Event
Market update
Published
03 Jun 2026 03:09
Source
BioSpace
Investing.com Direct company coverage

Lantern Pharma stock jumps on lung cancer trial survival data

Lantern Pharma Inc. (NASDAQ:LTRN) saw its shares rise after reporting extended survival data from its Phase 2 lung cancer trial. Patients treated with LP-300 plus chemotherapy achieved a median progression-free survival of 8.9 months, with over 70% experiencing tumor reduction. T

Tone
Positive 75/100
Event
Market update
Published
02 Jun 2026 14:40
Source
Investing.com
Stock Titan Direct company coverage

Lantern Pharma (LTRN) shares Harmonic LP-300 Phase 2 trial presentation in 8-K

Lantern Pharma Inc. (LTRN) filed an 8-K to furnish an investor-style presentation about its Harmonic™ Phase 2 clinical trial for the LP-300 product candidate. The presentation, used on June 1, 2026, is attached as Exhibit 99.1 and is designated as "furnished" rather than "filed,"

Tone
Neutral 50/100
Event
Market update
Published
02 Jun 2026 00:10
Source
Stock Titan
Finviz Direct company coverage

LTRN - Lantern Pharma Inc Stock Price and Quote

This article provides comprehensive stock information for Lantern Pharma Inc. (LTRN), including its current stock price, financial metrics, recent news, and insider transaction details. It highlights the company's focus on AI and machine learning for drug development, particularl

Tone
Positive 75/100
Event
Market update
Published
30 May 2026 02:09
Source
Finviz
ChartMill Direct company coverage

LTRN News | LANTERN PHARMA INC (NASDAQ:LTRN)

This article provides recent news and financial updates for Lantern Pharma Inc. (NASDAQ: LTRN). Key announcements include successful FDA Type C meeting results for its HARMONIC™ Phase 2 trial of LP-300, the report of Q1 2026 financial results, and two recent direct offerings tota

Tone
Positive 72/100
Event
Earnings
Published
29 May 2026 13:38
Source
ChartMill
ChartMill Direct company coverage

LTRN Technical Analysis | Trend, Signals & Chart Patterns | LANTERN PHARMA INC (NASDAQ:LTRN)

This article provides a technical analysis of LANTERN PHARMA INC (NASDAQ:LTRN), assigning it an overall technical rating of 8 out of 10. Both medium and short-term trends are positive, with the stock currently trading near the high end of its monthly range. However, the analysis

Tone
Positive 63/100
Event
Analyst action
Published
27 May 2026 00:10
Source
ChartMill
Market source Direct company coverage

Lantern Pharma Announces Successful Outcome of FDA Type C Meeting Request for HARMONIC™ Phase 2 Trial of LP-300 in Never-Smokers with NSCLC

Lantern Pharma announced that the FDA had no objections to its proposed amendments for the HARMONIC™ Phase 2 trial of LP-300. The amendments include focusing enrollment on patients with EGFR exon 21 L858R mutations, extending LP-300 dosing to eight cycles, and transitioning to a

Tone
Positive 88/100
Event
Market update
Published
19 May 2026 18:10
Source
Market source
BioSpace Direct company coverage

Lantern Pharma Reports First Quarter 2026 Financial Results and Provides Business Updates

Lantern Pharma reported its Q1 2026 financial results, showcasing a 47% reduction in R&D spend and a 27% decrease in net loss while advancing multiple clinical programs and launching its multi-agentic AI platform, withZeta.ai. The company also announced a strategic plan to separa

Tone
Positive 74/100
Event
Earnings
Published
18 May 2026 08:40
Source
BioSpace
Benzinga Direct company coverage

Lantern Pharma Inc (LTRN) Stock Price, Quote, News & History

This article provides a comprehensive overview of Lantern Pharma Inc. (LTRN) stock, including its current price ($2.99), market performance, key statistics, and recent news. It highlights the company's focus on developing oncology drug candidates using its AI platform and details

Tone
Positive 67/100
Event
Market update
Published
16 May 2026 19:40
Source
Benzinga
GuruFocus Direct company coverage

Lantern Pharma (LTRN) Q1 2026: EPS -$0.30 Beats Est. -$0.36; Revenue N/A -- What's the Valuation Signal?

Lantern Pharma Inc. (LTRN) reported a positive Q1 2026, with an EPS of -$0.30, beating analyst estimates of -$0.36. The company significantly reduced its net loss by 27% year-over-year and cut R&D expenses by 47%. Key milestones include FDA clearance for a pediatric CNS trial and

Tone
Positive 62/100
Event
Earnings
Published
15 May 2026 22:40
Source
GuruFocus